OPRX vs. RMNI, LLNW, RGP, LQDT, YEXT, XMTR, IMXI, DDI, OABI, and GRVY
Should you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include Rimini Street (RMNI), Limelight Networks (LLNW), Resources Connection (RGP), Liquidity Services (LQDT), Yext (YEXT), Xometry (XMTR), International Money Express (IMXI), DoubleDown Interactive (DDI), OmniAb (OABI), and Gravity (GRVY).
Rimini Street (NASDAQ:RMNI) and OptimizeRx (NASDAQ:OPRX) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations.
Rimini Street has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks.
73.8% of Rimini Street shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 41.3% of Rimini Street shares are held by insiders. Comparatively, 4.4% of OptimizeRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, OptimizeRx had 6 more articles in the media than Rimini Street. MarketBeat recorded 10 mentions for OptimizeRx and 4 mentions for Rimini Street. OptimizeRx's average media sentiment score of 0.75 beat Rimini Street's score of 0.64 indicating that Rimini Street is being referred to more favorably in the media.
Rimini Street presently has a consensus target price of $4.50, indicating a potential upside of 45.63%. OptimizeRx has a consensus target price of $16.07, indicating a potential upside of 48.40%. Given Rimini Street's stronger consensus rating and higher possible upside, analysts plainly believe OptimizeRx is more favorable than Rimini Street.
Rimini Street has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.
Rimini Street received 7 more outperform votes than OptimizeRx when rated by MarketBeat users. Likewise, 63.49% of users gave Rimini Street an outperform vote while only 63.48% of users gave OptimizeRx an outperform vote.
Rimini Street has a net margin of 5.02% compared to Rimini Street's net margin of -23.10%. Rimini Street's return on equity of -6.96% beat OptimizeRx's return on equity.
Summary
Rimini Street beats OptimizeRx on 11 of the 18 factors compared between the two stocks.
Get OptimizeRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptimizeRx Competitors List
Related Companies and Tools
